Across TCGA pan-cancer cohorts, NOL4L mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NOL4L data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NOL4L mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NOL4L expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where NOL4L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.396	0.585	.022	13	view →
HNSC	DFS	Median	II,III,IV	1.000	0.871	.015	9	view →
LSCC	OS	Tertile	II,III,IV	0.852	1.000	.014	8	view →
LUAD	DFS	Median	III,IV	0.319	0.654	.043	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: NOL4L tumor-vs-normal RNA expression · all NOL4L data types